PDSB vs. AURA, IVA, HRTX, RCKT, PRTA, ALLO, GLUE, TKNO, GOSS, and CRVS
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Aura Biosciences (AURA), Inventiva (IVA), Heron Therapeutics (HRTX), Rocket Pharmaceuticals (RCKT), Prothena (PRTA), Allogene Therapeutics (ALLO), Monte Rosa Therapeutics (GLUE), Alpha Teknova (TKNO), Gossamer Bio (GOSS), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.
PDS Biotechnology vs. Its Competitors
PDS Biotechnology (NASDAQ:PDSB) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
Aura Biosciences' return on equity of -58.63% beat PDS Biotechnology's return on equity.
PDS Biotechnology has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by company insiders. Comparatively, 5.4% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
PDS Biotechnology received 48 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 69.72% of users gave PDS Biotechnology an outperform vote while only 62.22% of users gave Aura Biosciences an outperform vote.
Aura Biosciences is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.
PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 447.11%. Aura Biosciences has a consensus target price of $22.00, suggesting a potential upside of 235.62%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, equities analysts clearly believe PDS Biotechnology is more favorable than Aura Biosciences.
In the previous week, PDS Biotechnology's average media sentiment score of 0.00 equaled Aura Biosciences'average media sentiment score.
Summary
PDS Biotechnology beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:PDSB) was last updated on 6/24/2025 by MarketBeat.com Staff
